Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: A meta-analysis

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Wang, Wei ^a   Zhang, Xiulan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB; MONOCLONAL ANTIBODY;

ADVERSE DRUG REACTION; AGE RELATED MACULAR DEGENERATION; ARTICLE; BENIGN TUMOR; CEREBROVASCULAR ACCIDENT; DRUG FATALITY; DRUG USE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERTENSION; INFECTION; INJURY; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; MORBIDITY; NEUROLOGIC DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; VEIN THROMBOSIS; VISUAL ACUITY; COMPARATIVE STUDY; MACULAR DEGENERATION; RISK;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; MACULAR DEGENERATION; RISK;

EID: 84908042259     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109744     Document Type: Article

References (41)

1. Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, et al. (2012) The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol 96: 752-756.
2. Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, et al. (2012) Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 119: 571-580.
3. Kawasaki R, Yasuda M, Song SJ, Chen SJ, Jonas JB, et al. (2010) The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 117: 921-927.
4. Schmier JK, Jones ML, Halpern MT (2006) The burden of age-related macular degeneration. Pharmacoeconomics 24: 319-334.
5. Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, et al. (2006) The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol 17: 257-266.
6. Ferris FR, Wilkinson CP, Bird A, Chakravarthy U, Chew E, et al. (2013) Clinical classification of age-related macular degeneration. Ophthalmology 120: 844-851.
7. Frampton JE (2013) Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration. Drugs Aging 30: 331-358.
8. Ambati J, Fowler BJ (2012) Mechanisms of age-related macular degeneration. Neuron 75: 26-39.
9. Lally DR, Gerstenblith AT, Regillo CD (2012) Preferred therapies for neovascular age-related macular degeneration. Curr Opin Ophthalmol 23: 182-188.
10. Campbell RJ, Bell CM, Campbell EL, Gill SS (2013) Systemic effects of intravitreal vascular endothelial growth factor inhibitors. Curr Opin Ophthalmol 24: 197-204.
11. Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, et al. (2010) Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr Opin Ophthalmol 21: 218-226.
12. Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, et al. (2013) Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist 18: 1004-1012.
13. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382: 1258-1267.
14. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119: 1388-1398.
15. Cheung CM, Wong TY (2013) Treatment of age-related macular degeneration. Lancet 382: 1230-1232.
16. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62: 1006-1012.
17. Abouammoh MA (2013) Ranibizumab injection for diabetic macular edema: meta-analysis of systemic safety and systematic review. Can J Ophthalmol 48: 317-323.
18. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
20. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
21. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
22. Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, et al. (2013) Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 120: 122-129.
23. Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, et al. (2013) Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology 120: 1860-1870.
24. DeCroos FC, Toth CA, Stinnett SS, Heydary CS, Burns R, et al. (2012) Optical coherence tomography grading reproducibility during the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology 119: 2549-2557.
25. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119: 1399-1411.
26. Grunwald JE, Daniel E, Ying GS, Pistilli M, Maguire MG, et al. (2012) Photographic assessment of baseline fundus morphologic features in the Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology 119: 1634-1641.
27. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364: 1897-1908.
28. Donahue SP, Recchia F, Sternberg PJ (2010) Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol 150: 287, 287.
29. Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, et al. (2009) Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am J Ophthalmol 148: 875-882.
30. Biswas P, Sengupta S, Choudhary R, Home S, Paul A, et al. (2011) Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol 59: 191-196.
31. Subramanian ML, Abedi G, Ness S, Ahmed E, Fenberg M, et al. (2010) Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye (Lond) 24: 1708-1715.
32. Krebs I, Schmetterer L, Boltz A, Told R, Vecsei-Marlovits V, et al. (2013) A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 97: 266-271.
33. Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-Cohen F, et al. (2013) Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial. Ophthalmology.
34. Mitchell P (2011) A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin 27: 1465-1475.
35. Aujla JS (2012) Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us? Clin Exp Optom 95: 538-540.
36. Torjesen I (2013) Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds. BMJ 347: f4678.
37. Campbell RJ, Gill SS, Bronskill SE, Paterson JM, Whitehead M, et al. (2012) Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ 345: e4203.
38. Campbell RJ, Bell CM, Paterson JM, Bronskill SE, Moineddin R, et al. (2012) Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis. Ophthalmology 119: 1604-1608.
39. French DD, Margo CE (2011) Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study. Retina 31: 1036-1042.
40. Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128: 1273-1279.
41. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, et al. (2012) A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 7: e42701.